Genelux (GNLX) Expected to Announce Earnings on Thursday

Key Points

• Genelux (NASDAQ:GNLX) is set to release its quarterly earnings on August 13th, with analysts predicting a loss of ($0.22) per share.
• The company's stock recently opened at $3.53, with a market cap of $133.29 million and a 12-month trading range spanning from $1.64 to $5.89.
• Analysts have a consensus rating of "Buy" for Genelux, with a price target of $17.75, while recent institutional buying suggests increasing interest in the stock.

Genelux (NASDAQ:GNLX - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Trading Down 5.7%

GNLX stock traded down $0.19 during midday trading on Friday, hitting $3.15. The company had a trading volume of 68,265 shares, compared to its average volume of 139,151. Genelux has a 52 week low of $1.93 and a 52 week high of $5.89. The stock's 50 day moving average price is $3.10 and its 200 day moving average price is $3.26. The stock has a market cap of $118.94 million, a price-to-earnings ratio of -3.66 and a beta of -0.32.

Analysts Set New Price Targets

Several analysts have weighed in on GNLX shares. Wall Street Zen upgraded Genelux from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Benchmark dropped their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research note on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Genelux in a research note on Wednesday, July 23rd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $17.75.

Hedge Funds Weigh In On Genelux

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new position in shares of Genelux in the 1st quarter worth about $239,000. Jane Street Group LLC purchased a new position in shares of Genelux in the 1st quarter worth about $190,000. Finally, Geode Capital Management LLC raised its position in shares of Genelux by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company's stock worth $915,000 after purchasing an additional 5,596 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company's stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.